tirzepatide for perimenopause The GLP-1/GIP dual-receptor agonist led to at least 15% loss of total body fat in premenopausal, perimenopausal, and postmenopausal women, but postmenopausal women taking menopausal hormone therapy had the greatest weight Perimenopausal and Postmenopausal Weight-Loss Challenges

Saxagliptin should be used with caution in: a

"While fat deposition in the liver is reversible in its early stages, its progression to NASH causes liver dysfunction, cirrhosis and increases the risk for liver cancer," said Dr Madhulika Tripathi, first author of the study, who is a senior research fellow with the Laboratory of Hormonal Regulation at Duke-NUS' Cardiovascular & Metabolic Programme

Verney C, Milosevic A, Alvarez C, Berger B (1993) Immunocytochemical evidence of well-developed dopaminergic and noradrenergic innervations in the frontal cerebral cortex of human fetuses at midgestation

This physiologic effect helps regulate postprandial glucose excursions and contributes to satiety and weight loss

The rising prevalence of diabetes is expected to propel the GLP-1 receptor agonist market going forward